Hanall Biopharma, Hankook Korus, and GC Wellbeing have received administrative penalties from the Ministry of Food and Drug Safety (MFDS) for failing to manage and supervise drug consignees properly.

According to the MFDS, the three companies outsourced drug production to other pharmaceutical companies but were penalized because the companies did not comply with the Pharmaceutical Affairs Act.

HanAll Biopharma outsourced the manufacturing process of Medisolu Inj., an autoimmune disease treatment, to Dongkwang Pharmaceutical.

The regulator found Dongkwang failed to comply with the test logbook regulation while manufacturing Medisolu. As a result, the ministry suspended the manufacture of Medisolu for three months.

GC Wellbeing also entrusted Dongkwang Pharmaceutical with the production of GC Multi 12 Inj., a vitamin supplement, and received a three-month manufacturing suspension as Dongkwang failed to comply with the test logbook regulation for the treatment as well.

Hankook Korus entrusted White Life Sciences with the manufacturing process of K Tova Tab., an arteriosclerosis solvent. White Life Sciences failed to comply with sample collection regulations during the manufacturing process, the ministry said.

As a result, the ministry imposed a three-month manufacturing ban on K Tova.